Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) shares were down 5.6% on Thursday . The company traded as low as $15.05 and last traded at $15.56. Approximately 68,373 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 201,986 shares. The stock had previously closed at $16.48.
Wall Street Analyst Weigh In
Several research analysts have issued reports on SION shares. Stifel Nicolaus started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price target on the stock. TD Cowen started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating on the stock. Finally, Guggenheim started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price target on the stock.
Get Our Latest Stock Report on SION
Sionna Therapeutics Stock Down 8.4 %
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Featured Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
